Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate pivekimab sunirine (PVEK) had a complete response, according to new data from the Phase I/II multicenter international CADENZA trial. The study was led by principal investigator and corresponding author Naveen Pemmaraju, M.D., professor of Leukemia, and senior author Naval Daver, M.D., professor of Leukemia.
“These strong, durable response results offer hope to BPDCN patients with limited treatment options,” Pemmaraju said. “An effective and safe frontline treatment for patients would be practice changing, and these positive results suggest that PVEK should be considered a potential standard treatment for BPDCN patients.”